Yasuhiro Nakagami

R&D Division, 1-2-58 Hiromachi, Shinagawa Ku
Hiromachi, 1408710, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Establishment of Irinotecan-Induced Oral Mucositis Hamster Model and Evaluation of Therapeutic Agents.

Establishment of Irinotecan-Induced Oral Mucositis Hamster Model and Evaluation of Therapeutic Agents.

Journal: Biological & pharmaceutical bulletin

Published: March 29, 2026

MA-5 ameliorates autism-like behavior in mice prenatally exposed to valproic acid.

MA-5 ameliorates autism-like behavior in mice prenatally exposed to valproic acid.

Journal: Behavioural pharmacology

Published: November 02, 2023

Discovery of DS-3801b, a non-macrolide GPR38 agonist with N-methylanilide structure.

Discovery of DS-3801b, a non-macrolide GPR38 agonist with N-methylanilide structure.

Journal: Bioorganic & medicinal chemistry letters

Published: November 16, 2021

A triterpenoid Nrf2 activator, RS9, promotes LC3-associated phagocytosis of photoreceptor outer segments in a p62-independent manner.

A triterpenoid Nrf2 activator, RS9, promotes LC3-associated phagocytosis of photoreceptor outer segments in a p62-independent manner.

Journal: Free radical biology & medicine

Published: February 20, 2020

NFE2L2 activator RS9 protects against corneal epithelial cell damage in dry eye models.

NFE2L2 activator RS9 protects against corneal epithelial cell damage in dry eye models.

Journal: PloS one

Published: September 28, 2019

Nrf2 Activator RS9 Suppresses Pathological Ocular Angiogenesis and Hyperpermeability.

Nrf2 Activator RS9 Suppresses Pathological Ocular Angiogenesis and Hyperpermeability.

Journal: Investigative ophthalmology & visual science

Published: May 04, 2019

An anti-PLVAP antibody suppresses laser-induced choroidal neovascularization in monkeys.

An anti-PLVAP antibody suppresses laser-induced choroidal neovascularization in monkeys.

Journal: European journal of pharmacology

Published: March 20, 2019

RS9, a novel Nrf2 activator, attenuates light-induced death of cells of photoreceptor cells and Müller glia cells.

RS9, a novel Nrf2 activator, attenuates light-induced death of cells of photoreceptor cells and Müller glia cells.

Journal: Journal of neurochemistry

Published: February 06, 2017

Nrf2 Is an Attractive Therapeutic Target for Retinal Diseases.

Nrf2 Is an Attractive Therapeutic Target for Retinal Diseases.

Journal: Oxidative medicine and cellular longevity

Published: July 20, 2016

Cytoprotective Effects of a Novel Nrf2 Activator, RS9, in Rhodopsin Pro347Leu Rabbits.

Cytoprotective Effects of a Novel Nrf2 Activator, RS9, in Rhodopsin Pro347Leu Rabbits.

Journal: Current eye research

Published: October 03, 2015

Novel Nrf2 activators from microbial transformation products inhibit blood-retinal barrier permeability in rabbits.

Novel Nrf2 activators from microbial transformation products inhibit blood-retinal barrier permeability in rabbits.

Journal: British journal of pharmacology

Published: July 17, 2014

RS-1748, a novel CC chemokine receptor 4 antagonist, inhibits ovalbumin-induced airway inflammation in guinea pigs.

RS-1748, a novel CC chemokine receptor 4 antagonist, inhibits ovalbumin-induced airway inflammation in guinea pigs.

Journal: Biological & pharmaceutical bulletin

Published: June 05, 2010

Showing 1-12 of 14

Last Updated: 09/26/2026